Please note: Forest Laboratories, Inc. is not responsible for
the content or services on the site you will now visit.
TEFLARO® is the First and Only IV Cephalosporin approved for ABSSSI and an IV Cephalosporin approved for CABP
Bactericidal Activity Against A Broad Spectrum of Gram-positive and Gram‑negative
Pathogens, Including MRSA* in ABSSSI and S. pneumoniae in CABP1
- Convenient q12h dosing in ABSSSI and CABP1
- 600 mg intravenous over 5-60 minutes
- Treatment duration
- 5-14 days for ABSSSI
- 5-7 days for CABP
*TEFLARO is indicated for ABSSSI due to MRSA. It is not indicated for CABP due to MRSA. MSSA=Methicillin-susceptible Staphylococcus aureus. MRSA=Methicillin-resistant Staphylococcus aureus. *There are insufficient historical data to establish the magnitude of drug effect for antibacterial drugs compared with placebo at a TOC time point. Etest® is a registered trademark of BioMérieux §MSSA=Methicillin-susceptible Staphylococcus aureus. Clinical efficacy of TEFLARO in treating CABP due to MRSA has not been studied.